The distinct effects of vilazodone on the 5-HTT and 5-HT1A receptors may enhance serotonergic transmission to achieve clinical efficacy in depression while limiting the adverse events of SSRI-induced sexual dysfunction. This evidence concerns the gene HTR1A and depressive disorder.